Phase 3
N=300
The Effect of Pretreatment With Roc on Succinylcholine Myalgias
Myalgia
Bottom Line
View on ClinicalTrials.gov: NCT04581395 ↗Enrolled (actual)
300
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Myalgias Perceived at 3 Hours — 81; 83; 83; 15 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- non-pretreated Succinylcholine (Other); succinylcholine 1 minute after rocuronium pretreatment (Drug); succinylcholine 2 minutes following rocuronium pretreatment (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Indiana University
- Primary completion
- Apr 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Myalgias Perceived at 3 Hours |
81; 83; 83; 15; 13; 15 | — |
| PRIMARY Myalgias at 24 Hours Post Succinylcholine Administration. |
64; 78; 80; 32; 18; 18 | — |
| PRIMARY Pain Scores |
64; 78; 80; 20; 9; 16 | — |
| PRIMARY Pain Scores |
64; 78; 80; 20; 9; 16 | — |
| SECONDARY Number of Participants With Observed Presence of Muscle Fasciculation Following Succinylcholine Administration |
75; 20; 13 | — |
Summary
Succinylcholine is a medication (depolarizing muscle relaxant) that is used as part of an anesthetic (going to sleep for surgery). This medication can cause significant muscle soreness. Rocuronium is a medication (non-depolarizing muscle relaxant) that some anesthesia providers believe may reduce muscle soreness caused by succinylcholine if given prior, but this has been controversial. Some anesthesiologists pretreat patients with rocuronium before giving patients succinylcholine, and some do not. The purpose of this study is to examine the effect of pretreatment with rocuronium on muscle soreness associated with succinylcholine administration.
Eligibility Criteria
Inclusion Criteria
- Undergoing elective Endoscopic Retrograde Cholangiopancreatography (ERCP) under general anesthesia
- Have been informed of the nature of the study and informed consent has been obtained
Exclusion Criteria
- Patients will be excluded if they have chronic pain requiring daily opioid use greater than 30 mg PO morphine equivalent.
- Patients will also be excluded if their comorbid medical conditions require a true rapid sequence induction as precurarization with rocuronium increases the time to intubation which is undesirable in a patient who is at high risk for aspiration.
- Patients taking muscle relaxants at home for spasticity.
- Patients under the age of 18 years old.
- Any contraindication for using succinylcholine or rocuronium.
Data sourced from ClinicalTrials.gov (NCT04581395). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.